Type 2 diabetes is one of the main causes of disease and mortality in the world.Its development is closely related to insulin resistance induced by obesity, which prevents the body from correctly using glucose as a source of energy.
A recent study published in the prestigious Science magazine has identified the adrenomedulin hormone as a key factor in systemic resistance to insulin in people with obesity and type 2 diabetes. These findings suggest that blocking the effects of this hormone could improve controlof glucose and represent a new therapeutic approach for this metabolic disease.
Insulin resistance mainly affects key metabolism tissues, such as adipose tissue, skeletal muscle and liver.However, this study has revealed a new protagonist in this metabolic dysfunction: the endothelial cells of the blood vessels.
The researchers found that adrenomedulin and factor H levels of the complement (CFH), a protein that enhances its effects, are elevated in the blood of humans and obese mice.In human endothelial cells, adrenomedulin inhibits insulin signaling by deactivating its receiver, which suggests its participation in insulin resistance in blood vessels.
To analyze the impact of adrenomedulin, scientists treated thin mice with this hormone and observed that they developed insulin resistance and poor glucose control, simulating the conditions of obesity.
On the other hand, by eliminating adrenomedulin receptors in the blood vessels of the mice, this effect was prevented.In addition, the locking of adrenomedulin signaling improved the function of insulin in blood vessels, favored muscle blood flow and avoided insulin resistance in obese mice.
These results open the door to future research that could lead to the development of new therapeutic strategies to improve glycemic control in people with type 2 diabetes.
What do you think of these findings?
Do you think it could be a significant advance in the treatment of type 2 diabetes?
We read you!👉🏻
